ArticleJournal of pharmaceutical policy and practice2021
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.
Article in Journal of pharmaceutical policy and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Pharmaceutical regulatory harmonization in Africa: a scoping review of policy design, implementation approaches, and outcomes.Frontiers in medicine · 2026Pooled it
- MPOX outbreak in Africa: the urgent need for local manufacturing of the vaccine and decolonized health systems.BMC public health · 2025Pooled it
- Antimicrobial prescription patterns in East Africa: a systematic review.Systematic reviews · 2023Pooled it
- Substandard and Falsified Medicines, Regulatory Capacity and Public Health: A Narrative Review With a Focus on Africa.Public health challenges · 2026Review
- Stakeholder Perceptions on Innovative Private Pharmacy Distribution Channels and Implications for Medicine Quality in Zambia: A Qualitative Study.Global health, science and practice · 2026Article
- New approach methodologies for next-generation risk assessment of nanomaterials and nano-enabled products.Nano convergence · 2026Review
- Veterinary fixed-dose antibiotics in Africa: a need for evidence-based regulation.Veterinary research · 2026Article
- Health Diplomacy in Africa: Prospects, Obstacles, and the Way Ahead.Public health challenges · 2026Review
- Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use.Clinical pharmacology and therapeutics · 2026Review
- Self-care strategies and interventions to address antimicrobial resistance: evidence review and recommendations for national programs, service providers, caregivers, and self-carers.Frontiers in public health · 2026Review
- Adoption of international good manufacturing practices in the Nigerian pharmaceutical industry: promising results from a decade of investment.Journal of pharmaceutical policy and practice · 2026Review
- Advancing the inclusion of pregnant and lactating populations in HIV PrEP research: ethical, regulatory, and surveillance recommendations from a multisectoral working group.Frontiers in public health · 2026Article
- Exploring factors affecting access to non-communicable disease medicines in low- and middle-income countries: a systematic review.BMJ public health · 2026Article
- The registration status of maternal, newborn, and child health medical products: evidence from 9 countries.Journal of pharmaceutical policy and practice · 2026Article
- An analysis of the registration of essential medicines in Namibia: a proxy measure of the availability of essential medicines.Journal of pharmaceutical policy and practice · 2026Article
- The evolving landscape of cardiovascular health in Africa: insights from WHO AFRO.Nature medicine · 2026Article
- Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.Frontiers in pharmacology · 2026Article
- Prevalence and Factors Associated With the Informal Market for Medicines in Benin: A Community-Based Cross-Sectional Study.Health science reports · 2025Article
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Antiretroviral Use for HIV Prevention During Pregnancy: The Need to Strengthen Regulatory and Surveillance Systems in Africa.Drug safety · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insufficient access to quality, safe, efficacious and affordable medical products in Africa has posed a significant challenge to public health for decades. In part, this is attributed to weak or absent policies and regulatory systems, a lack of competent regulatory professionals in National Medicines Regulatory Authorities (NMRAs) and ineffective regional collaborations among NMRAs. In response to national regulatory challenges in Africa, a number of regional harmonisation efforts were introduced through the African Medicines Regulatory Harmonisation (AMRH) initiative to, among others, expedite market authorisation of medical products and to facilitate the alignment of national legislative frameworks with the AU Model Law on Medical Products Regulation. The goals of the model law include to increase collaboration across countries and to facilitate the overall regional harmonisation process. The AMRH initiative is proposed to serve as the foundation for the establishment of the African Medicines Agency (AMA). The AMA will, as one of its mandates, coordinate the regional harmonisation systems that are enabled by AU Model Law domestication and implementation. In this paper, we review the key entities involved in regional and continental harmonisation of medicines regulation, the milestones achieved in establishing the AMA as well as the implementation targets and anticipated challenges related to the AU Model Law domestication and the AMA's establishment. This review shows that implementation targets for the AU Model Law have not been fully met, and the AMA treaty has not been ratified by the minimum required number of countries for its establishment. In spite of the challenges, the AU Model Law and the AMA hold promise to address gaps and inconsistencies in national regulatory legislation as well as to ensure effective medicines regulation by galvanising technical support, regulatory expertise and resources at a continental level. Furthermore, this review provides recommendations for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.